FDA Approves Interchangeable Biosimilar Insulin Product to Treat Diabetes
By Stephen Nakrosis
The U.S. Food and Drug Administration on Wednesday said it
approved the first interchangeable biosimilar insulin product.
The FDA said it granted approval of the product, Semglee, to
Mylan Pharmaceuticals Inc.
Semglee, or insulin glargine-yfgn, is biosimilar to and can be
substituted for Lantus, or insulin glargine, the FDA said.
"Approval of these insulin products can provide patients with
additional safe, high-quality and potentially cost-effective
options for treating diabetes," the FDA said.
More than 34 million people in the U.S. today have been
diagnosed with diabetes, according to the FDA.
-Write to Stephen Nakrosis at firstname.lastname@example.org
(END) Dow Jones Newswires
July 28, 2021 18:37 ET (22:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.